Search
People
Timo LassmannFeilman Fellow; Head, Precision Health Research and Head, Computational Biology
Research
It is more “unbalanced” than you thinkSébastien Malinge PhD Laboratory Head, Translational Genomics in Leukaemia, Ursula Kees Fellow (CCRF), Cancer Council WA Fellow (CCWA), Senior
Research
Cochrane corner: platinum-induced hearing loss after treatment for childhood cancerThis systematic review shows that children treated with platinum analogues are at risk of developing hearing loss
Research
Regular exercise improves the well-being of parents of children with cancerMental health benefits of a pedometer-based exercise intervention for parents of children with cancer were identified.
Research
CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangementsIdentified CCI-007 as a novel small molecule that displays rapid toxicity towards a subset of MLL-r, CALM-AF10 and SET-NUP214 leukemia cell lines
Research
Risk of cancer among children with birth defects: A novel approachThis novel approach aimed to prevent inflated hazard ratios arising from reverse causation, and allow identification of associations beyond those already...
Research
The role of CCN family genes in haematological malignanciesHaematological malignancies, although a broad range of specific disease types, continue to show considerable overlap in classification, and patients are...
Research
Brain TumourBrain tumours are the second most common cancer in children (after leukaemia).
Research
MelanomaMelanoma, also known as malignant melanoma, occurs when abnormal skin cells multiply rapidly in an uncontrolled way.
Research
Psychosocial Outcomes in Parents of Children with Acute Lymphoblastic Leukaemia in Australia and New Zealand Through and Beyond TreatmentParents of children with acute lymphoblastic leukaemia (ALL) experience emotional distress throughout their child's treatment course. This study describes the psychological experience of Australian and New Zealand parents of children diagnosed with ALL.